Opthea Terminates Sozinibercept Development After Failed Phase 3 Trials

MT Newswires Live03-31

Opthea (OPT) said Monday that a phase 3 trial evaluating the efficacy and safety of 2 mg sozinibercept for wet age-related macular degeneration failed to meet its primary endpoint of improved visual acuity.

The announcement is the second blow for the company as another phase 3 failed to meet its primary goal last week.

Opthea and its Development Funding Agreement investors have agreed to immediately discontinue the development of sozinibercept for wet age-related macular degeneration, the company said.

It added that the decision does not trigger a termination event under the Development Funding Agreement, meaning no payment is required to be made by Opthea.

The company said it continues discussions with Development Funding Agreement investors to explore potential options for its future.

Opthea estimates it will have $100 million in cash and cash equivalents by the end of March 2025 but faces uncertainty about its ability to continue as a going concern, the drug developer said.

The ASX will suspend trading of Opthea's securities until the company clarifies further.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2523956912?lang=en_US&edition=full_marsco","thumbnail":"","is_english":true,"pubTime":"2025-03-31 18:58","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2523956912","market":"sg","top_or_hot":-1,"title":"Opthea Terminates Sozinibercept Development After Failed Phase 3 Trials","media":"MT Newswires Live","content":"<html><body><p> Opthea (OPT) said Monday that a phase 3 trial evaluating the efficacy and safety of 2 mg sozinibercept for wet age-related macular degeneration failed to meet its primary endpoint of improved visual acuity.</p><p>The announcement is the second blow for the company as another phase 3 failed to meet its primary goal last week.</p><p>Opthea and its Development Funding Agreement investors have agreed to immediately discontinue the development of sozinibercept for wet age-related macular degeneration, the company said.</p><p>It added that the decision does not trigger a termination event under the  Development Funding Agreement, meaning no payment is required to be made by Opthea.</p><p>The company said it continues discussions with  Development Funding Agreement investors to explore potential options for its future.</p><p>Opthea estimates it will have $100 million in cash and cash equivalents by the end of March 2025 but faces uncertainty about its ability to continue as a going concern, the drug developer said.</p><p>The ASX will suspend trading of Opthea's securities until the company clarifies further.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Opthea Terminates Sozinibercept Development After Failed Phase 3 Trials</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nOpthea Terminates Sozinibercept Development After Failed Phase 3 Trials\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-03-31 18:58</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Opthea (OPT) said Monday that a phase 3 trial evaluating the efficacy and safety of 2 mg sozinibercept for wet age-related macular degeneration failed to meet its primary endpoint of improved visual acuity.</p><p>The announcement is the second blow for the company as another phase 3 failed to meet its primary goal last week.</p><p>Opthea and its Development Funding Agreement investors have agreed to immediately discontinue the development of sozinibercept for wet age-related macular degeneration, the company said.</p><p>It added that the decision does not trigger a termination event under the  Development Funding Agreement, meaning no payment is required to be made by Opthea.</p><p>The company said it continues discussions with  Development Funding Agreement investors to explore potential options for its future.</p><p>Opthea estimates it will have $100 million in cash and cash equivalents by the end of March 2025 but faces uncertainty about its ability to continue as a going concern, the drug developer said.</p><p>The ASX will suspend trading of Opthea's securities until the company clarifies further.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7067","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2523956912","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2523956912","pubTimestamp":1743418697,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Opthea  said Monday that a phase 3 trial evaluating the efficacy and safety of 2 mg sozinibercept for wet age-related macular degeneration failed to meet its primary endpoint of improved visual acuity.The announcement is the second blow for the company as another phase 3 failed to meet its primary goal last week.Opthea and its Development Funding Agreement investors have agreed to immediately discontinue the development of sozinibercept for wet age-related macular degeneration, the company said.It added that the decision does not trigger a termination event under the  Development Funding Agreement, meaning no payment is required to be made by Opthea.The company said it continues discussions with  Development Funding Agreement investors to explore potential options for its future.Opthea estimates it will have $100 million in cash and cash equivalents by the end of March 2025 but faces uncertainty about its ability to continue as a going concern, the drug developer said.The ASX will susp","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7067":"生物科技","OPT":"Opthea Ltd","BK7508":"医药生物股","BK4139":"生物科技","OPT.AU":"OPTHEA LTD"},"translate_title":"Opthea在3期试验失败后终止Sozinibercept开发","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"OPT":1,"OPT.AU":1},"content_text":"Opthea (OPT) said Monday that a phase 3 trial evaluating the efficacy and safety of 2 mg sozinibercept for wet age-related macular degeneration failed to meet its primary endpoint of improved visual acuity.The announcement is the second blow for the company as another phase 3 failed to meet its primary goal last week.Opthea and its Development Funding Agreement investors have agreed to immediately discontinue the development of sozinibercept for wet age-related macular degeneration, the company said.It added that the decision does not trigger a termination event under the  Development Funding Agreement, meaning no payment is required to be made by Opthea.The company said it continues discussions with  Development Funding Agreement investors to explore potential options for its future.Opthea estimates it will have $100 million in cash and cash equivalents by the end of March 2025 but faces uncertainty about its ability to continue as a going concern, the drug developer said.The ASX will suspend trading of Opthea's securities until the company clarifies further.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.33.2","shortVersion":"4.33.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2523956912"}